KALV · KalVista Pharmaceuticals, Inc. · Stock research

Current Thesis

KALV is a resolved takeout, not a live security. Chiesi Farmaceutici S.p.A.'s $27.00/share all-cash acquisition closed on 2026-06-11, with KalVista continuing as a wholly owned Chiesi subsidiary. The second-step merger converted the remaining stock into the same $27.00 cash. Shares ceased trading on the Nasdaq Global Market before the open on 2026-06-11, and the wind-down has since advanced a POS AM has been filed to deregister the shelf securities, Form 4 filings show directors and officers cashing out options at the $27.00 price, and Form 15 deregistration under the Exchange Act follows Nasdaq's Form 25. There is no spread, no momentum leg, and no listed share this file stays open only so a stale price feed doesn't resurface a delisted ticker as a fresh breakout.

Bullish and bearish views on KalVista Pharmaceuticals, Inc.

The model's bull view on KalVista Pharmaceuticals, Inc. (KALV), in brief: The deal completed clean and ahead of the original timeline. The bear view: There is nothing to trade. The equity is delisted and mid-deregistration (POS AM filed, Form 25 lodged, Form 15 pending). Any momentum, breakout, or mean-reversion read is now arithmetic on a frozen tape. The franchise is private. Listed exposure to EKTERLY and the HAE… Both cases follow in full.

Bull Case

• The deal completed clean and ahead of the original timeline. Announced 2026-04-29 at a 36% premium to the 30-day VWAP (~$1.9B), the transaction cleared every regulator early US HSR waiting period expired 2026-05-28, Germany's FCO declined to meet GWB prohibition criteria 2026-05-27, Italy's FDI authority confirmed no objection 2026-05-29 then closed 2026-06-11, faster than the initial Q3-2026 placeholder. Tendering holders received $27.00 cash;
• The underlying asset was real, which is why the arb never wobbled. EKTERLY (sebetralstat), the first oral on-demand therapy for hereditary angioedema, booked roughly $49M FY2025 net revenue (~$35M in Q4 2025 alone) with 1,702 patient start forms, ~20% US HAE penetration, and 724 prescribers through 2026-02-28, plus Japan (Kaken), Germany and UK launches underway in 2026. That revenue floor kept deal-break odds negligible into the close.
• The convertible tail settled at parity. Holders of the 3.250% Convertible Senior Notes due 2031 received the right to convert each $1,000 note into $1,606.28 cash, aligning the credit with the $27.00 equity consideration a clean settlement, not a residual claim.

Bear Case

• There is nothing to trade. The equity is delisted and mid-deregistration (POS AM filed, Form 25 lodged, Form 15 pending). Any momentum, breakout, or mean-reversion read is now arithmetic on a frozen tape.
• The franchise is private. Listed exposure to EKTERLY and the HAE rare-disease theme through this name is gone; it sits inside Chiesi's privately held portfolio, unreachable via a public share.
• The whole arc was a cap-and-crash payoff, never a trend. From the 2026-04-29 announcement gap into the close, the stock offered a sub-2% capped spread to $27.00 against roughly 40% deal-break reversion toward $15–16 (52-week low $9.83) pennies of upside in front of binary downside, with zero trend velocity for a momentum book to work with.
• Stale-data risk is the only remaining hazard. A screen keyed to pre-delisting prices will keep flagging KALV near its 52-week high and above every moving average a phantom breakout with no liquidity behind it.

Setup & Price Structure

• Terminal print: $27.00 cash. The last Nasdaq tape stopped before the 2026-06-11 open; there is no live quote, no bid/ask, and no float to accumulate. Shares outstanding were 53,240,888 as of 2026-05-06; ~43.15M tendered.
• Moving-average / RSI reads are meaningless. Any indicator will compute off the frozen $27.00 level and report the name "above all MAs / near 52-week high." Treat every such signal as a data artifact, not a setup this ticker will trip breakout rules with no tradability behind them.
• No reversion path. A completed short-form merger plus deregistration does not unwind; there is no scenario in which the stock relists and re-prices absent a deal reversal, which has no precedent here.

Catalyst Calendar (next 30 days)

• No earnings, no FDA/PDUFA, no analyst catalysts. H.C. Wainwright had already cut to Neutral on the merger (de-rating, no standalone story); coverage is winding down. There is no dated catalyst that produces a tradeable move, because there is no listed share.

Elapsed catalysts

• Form 15 deregistration effectiveness (~2026-07/08, est.): completes suspension of Exchange Act reporting following the 2026-06-11 Form 25 delisting. Administrative only no tradeable event. _(passed 38d ago)_

What Would Change Our Mind

The read reopens only on a genuine relisting event: a definitive merger termination or reversal that returns KALV to a US exchange with a live quote, restored SEC reporting, and real float. A daily close below $27.00 can no longer print the stock is delisted at the $27.00 cash consideration and the merger is closed. Short of a formal deal unwind (no precedent in this situation), nothing about EKTERLY's launch trajectory, HAE competitive dynamics, or Chiesi's private strategy is expressible through a tradeable KALV share, so none of it changes the stance: there is no security here.

Correlation Notes

• Special-situation, not thematic, exposure while it lived. During the deal window KALV traded off deal-completion odds, not the biotech tape (XBI) or rates its correlation to sector beta was near zero by design. Post-close it correlates with nothing; it is a settled cash event.
• HAE / rare-disease read-through goes elsewhere. Investors wanting listed exposure to the oral-HAE thesis EKTERLY validated must look to peers still on-exchange (e.g. the broader plasma-kallikrein and C1-inhibitor complex); KALV no longer carries that beta.
• Watchlist hygiene: flag as delisted/closed so the name is excluded from breakout and momentum scans; any signal it generates is a stale-price false positive.